Table 1 Demographic and clinical characteristics of study.

From: Neural correlates of personal space regulation in psychosis: role of the inferior parietal cortex

 

HC (n = 60)

PD (n = 37)

Test statistic

P

Gender (% female)

35.0

29.7

X2 (1, N = 97) = 0.288

0.592

Age (yrs)

26.12 (5.53)

27.81 (6.24)

t(95) = −1.395

0.166

Parental Education (yrs)

15.58 (3.33)

15.78 (2.86)

t(95) = −0.304

0.762

Full-Scale IQ

109.92 (7.44)

106.71 (9.75)

t(95) = 1.822

0.072

PANSS 5 Factor: Positive factor (4 items)

—

2.47 (0.18)

 

—

PANSS 5 Factor: Negative factor (6 items)

—

2.20 (0.16)

 

—

PANSS 5 Factor: Disorganized factor (3 items)

—

2.15 (0.14)

 

—

PANSS 5 Factor: Excited factor (4 items)

—

1.58 (0.10)

 

—

PANSS 5 Factor: Depressed factor (3 items)

—

2.69 (0.18)

 

—

Illness Duration (yrs)

—

7.49 (6.03)

 

—

CPZ equivalents (mg)

—

253.93 (352.83)

 

—

  1. Variables-of-interest are listed in left-most column for the Healthy Control (HC) and Psychotic Disorder (PD) groups, with the mean (standard deviation) and between-group difference significance (independent t-test) provided. Variables include: gender (percentage of females), mean age (years), mean parental education (years), mean full-scale intelligence quotient (IQ; American National Adult Reading Test score), and, for the PD group only, mean scores on the Positive and Negative Syndrome Scale (PANSS) Five Factor subscales (positive, negative, disorganized, excited, and depressed), mean illness duration (years), and mean chlorpromazine (CPZ) equivalents. The 37 PD subjects whose data were included in the analyses (subjects were excluded if found to have brain structural abnormalities (1 PD excluded) or very poor task performance during scanning (2 PD excluded); see Supplementary Materials for exclusion criteria) had the following primary diagnoses: schizophrenia (n = 17), schizoaffective disorder (n = 9), and bipolar disorder with psychotic features (n = 11). The participants of the PD group were treated with the following antipsychotic medications: 43.2% (n = 16) aripiprazole, 13.5% (n = 5) clozapine, 13.5% (n = 5) olanzapine, 21.6% (n = 8) none, and the remaining 18.9% (n = 7) were being treated with one of the following medications: risperidone, quetiapine, lurasidone*, ziprasidone*, perphenazine, haloperidol, cariprazine, or paliperidone palminate (* same individual).
Back to article page